Member Info for Mars1

Can travel quickly when on a “trajectory “

Snap

A reminder what we are waiting for that has a global £5BN market. Looking at the timescales not long now for a lot of action. Be out at your peril.

RNS 3/12/18
“
·    Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions
·     In addition, NXP002 demonstrated specific action measured against key inflammatory targets
·     NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidon)
RNS 25/10/19
“It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.”
RNS 25/11
“Nuformix is putting in place the team and development partnerships to pursue this path for NXP002. Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US.”
RNS 24/12
“
·     NXP002 progression towards clinic
o  Partnerships in place to support development of NXP002 as an inhaled therapy for Idiopathic Pulmonary Fibrosis ("IPF") and IPF-induced cough
o  Discussions with development partners commenced
o  Assembling expert team to progress to patient studies”

Dan has in the past turned down a podcast when news was about to drop

Buying through morning just got NT message

Just been offered 6.24 to buy

Amazing the speculation surrounding the change of director. It is possible DT has sacrificed himself for the Chinese relationship ie all previous relationships with the ex NSB chair had to be closed. It matters not. DT had the original NSB relationship and probably key to getting NFX up and running job done. Vacancy for 2 NEDS where do you want to sell the business US is probable, then is it Europe or Asia, while Asia seems a ready market already. Other question would Be the extended China deal was it Yatai or old NSB? One would think projects would be Yatai approved.

Well that is NHS confirmation

Augustus this has already been pointed out but if you look at the link in young bucks post at 17.23 you will see the lab in Spain is using Primerdesign as recommended by the cdc

Imagine the impact on the sp if FDA approval is given to save every US citizen

All tests must be performed centrally by CDC until FDA approval then it can be tested throughout the US using the CDC test

See the post from young buck at 17.23 confirms that the Spanish firm are using Primerdesign as recommended by cdc so yes there is an evidence trail

Anyone know the close price on Paris or Frankfurt markets

Will ano RNS be issues, this was what was said the 31st Jan RNS;
Graham Mullis, Chief Executive Officer of Novacyt commented.

"Over the last few days, we have seen significant early demand for our genesig® 2019-nCoV test from over 10 countries.
It does not say interest it says demand from over ten countries ie orders so why are we expecting ano RNS. That may already include the UK. Not every company wil be client specific. That must have included the majority of countries affected at the time.

Should be a lot of ‘live’ test data for submission to the FDA if the labs are prepared to provide copies of their results

Han**** Health Minister in H of Commons this is a marathon not a sprint

Just seen BBC news, citizens in China who are ill are been kept at home due to lack of tests and beds

Interesting how every country feels obligated to repatriate citizens when there is a global virus and not contain it at source. Humanitarian not logical especially when the receiving ground staff have no protection. Am I being harsh?
https://www.google.co.uk/amp/s/www.nbcnews.com/news/amp/ncna1127226

Latest drug for Kissei has not had a successful phase 3 test.
https://www.kissei.co.jp/e_contents/news/2020/20200122-3514.html

No 3 market in the world. Worth a read. Deregulation is also a feature in Japan as is an ageing population.
https://www.cphi.com/japan/visit/news-and-updates/did-you-know-six-facts-about-japanese-pharma-industry